The mean (%CV) tenofovir Cmax and AUC0-∞ values were 223 (34.8%) ng/ ml and 2,050 (50.8%) ng• h/ ml, respectively, in normal subjects compared with 289 (46.0%) ng/ ml and 2,310 (43.5%) ng• h/ ml in subjects with moderate hepatic impairment, and 305 (24.8%) ng/ ml and 2,740 (44.0%) ng• h/ ml in subjects with severe hepatic impairment.
Keskmised (sulgudes hälbekoefitsient) tenofoviiri Cmax- i ja AUC0- ∞ väärtused olid tervetel isikutel vastavalt 223 (34, 8%) ng/ ml ja 2050 (50, 8%) ng• h/ ml võrreldes vastavate näitajatega 289 (46, 0%) ng/ ml ja 2310 (43, 5%) ng• h/ ml mõõduka ning 305 (24, 8%) ng/ ml ja 2740 (44, 0%) ng• h/ ml raske maksafunktsiooni kahjustusega patsientidel.